HEB, Hemispherx Biopharma (AMEX)NEW Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HEB, Hemispherx Biopharma (AMEX)NEW

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: MarcG who wrote (58)	11/17/1997 12:42:00 PM
From: MarcG	Read Replies (1) of 857

Industry News: A new type of hepatitis, hepatitis-E, has been discovered in the U.S. by the Mayo Clinic and Abbot Labs. This is the first time that a hepatitis strain has not been traced to a foreign country. The new type of this disease has been named HEV-US-1. The letter of intent for collaborative efforts on the hepatitis front have been announced between Hemispherx Biopharma (HEB) and Beaufor Ipsen. Will the discovery of this new type open up a new application for Ampligen, and if so, will the same JV partner be involved or will new ones be pursued? MG:

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next